FLT3 and acute myeloid leukemia: Although the addition of sorafenib to intensive chemotherapy did not show clinical benefits in a phase II trial [20], several studies demonstrated the efficacy of sorafenib as a maintenance therapy post-allogeneic stem cell transplantation for FLT3-ITD-positive AML [21,22,23].